drugset
drugset / Trial / NCT01083290

Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets

NCT01083290 ↗

Phase 1 Completed 14 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelBasic science

Summary

Objective is to investigate pharmacokinetics and to estimate the level of dose linearity of spironolactone and its metabolites canrenone and 7α-thiomethylspirolactone from Spironolactone 25 mg, 50 mg and 100 mg Tablets

Timeline

Start
2010-04
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 25 mg —
Subject Spironolactone Small molecule 50 mg —
Subject Spironolactone Small molecule 100 mg —

Indications

No indication recorded.